31 results
424B5
TLSA
Tiziana Life Sciences Ltd
1 Sep 23
Prospectus supplement for primary offering
5:16pm
has been observed to have a higher affinity for the soluble IL-6R from antibody binding studies conducted in cell culture. TZLS-501 also demonstrated
F-3/A
oehiffnt7p61i14i427
25 Feb 22
Shelf registration (foreign) (amended)
4:10pm
F-3/A
8o3j4w7dl4nwzq49p
1 Feb 22
Shelf registration (foreign) (amended)
4:15pm
F-3
qzdsw fjkf1g1e
26 Jan 21
Shelf registration (foreign)
5:31pm
6-K
EX-99.1
3ga8xf4p yrbubabrrn
30 Sep 20
Interim Results for the Six Months Ended 30 June 2020
6:11am
424B5
2s7zscg
4 Aug 20
Prospectus supplement for primary offering
4:35pm
6-K
EX-99.1
ihw4x9 dra
18 Jun 20
Final Results for the Year Ended 31 December 2019
7:01am
424B5
fcc 3yymq2ui1l4jxsg
10 Apr 20
Prospectus supplement for primary offering
5:22pm
424B5
0yklo40
14 Feb 20
Prospectus supplement for primary offering
12:00am
F-3/A
9d572zf2r9od97z1znu7
30 Jan 20
Shelf registration (foreign) (amended)
4:47pm
F-3
efuxmsjoh
22 Jan 20
Shelf registration (foreign)
4:31pm
6-K
EX-99.1
8haj51h11cz40jq5
30 Sep 19
Interim Results for the Six Months Ended 30 June 2019
7:55am
F-1/A
1uagb5yw6r7iviq
20 Sep 19
Registration statement (foreign) (amended)
4:51pm
F-1/A
oupery2fpq70207rw19
17 Sep 19
Registration statement (foreign) (amended)
5:19pm